Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Gulley Website

James L. Gulley, M.D., Ph.D.

Selected Publications

1)  Jochems C, Tucker JA, Tsang KY, Madan RA, Dahut WL, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J.
A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.
Cancer Immunol. Immunother. 63: 407-18, 2014.
[Journal]
2)  Farsaci B, Jochems C, Grenga I, Donahue RN, Tucker JA, Pinto PA, Merino MJ, Heery CR, Madan RA, Gulley JL, Schlom J.
Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets.
Int. J. Cancer. 2014.
[Journal]
3)  Singh BH, Gulley JL.
Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications.
Asian J. Androl. 2014.
[Journal]
4)  O'Sullivan Coyne G, Madan RA, Gulley JL.
Nivolumab: promising survival signal coupled with limited toxicity raises expectations.
J. Clin. Oncol. 32: 986-8, 2014.
[Journal]
5)  Kim PS, Jochems C, Grenga I, Donahue RN, Tsang KY, Gulley JL, Schlom J, Farsaci B.
Pan-Bcl-2 Inhibitor, GX15-070 (Obatoclax), Decreases Human T Regulatory Lymphocytes while Preserving Effector T Lymphocytes: A Rationale for Its Use in Combination Immunotherapy.
J. Immunol. 192: 2622-33, 2014.
[Journal]
6)  Roselli M, Cereda V, di Bari MG, Formica V, Spila A, Jochems C, Farsaci B, Donahue R, Gulley JL, Schlom J, Guadagni F.
Effects of conventional therapeutic interventions on the number and function of regulatory T cells.
Oncoimmunology. 2: e27025, 2013.
[Journal]
7)  Bilusic M, Heery CR, Arlen PM, Rauckhorst M, Apelian D, Tsang KY, Tucker JA, Jochems C, Schlom J, Gulley JL, Madan RA.
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.
Cancer Immunol. Immunother. [Epub ahead of print], 2013.
[Journal]
8)  Madan RA, Gulley JL.
Prostate cancer: Intermediate efficacy end points to assess modern therapies.
Nat Rev Urol. 10: 686-7, 2013.
[Journal]
9)  Madan RA, Gulley JL, Kantoff PW.
Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.
Cancer J. 19: 50-8, 2013.
[Journal]
10)  Rojan A, Funches R, Regan MM, Gulley JL, Bubley GJ.
Dramatic and prolonged PSA response after retreatment with a PSA vaccine.
Clin Genitourin Cancer. 11: 362-4, 2013.
[Journal]
11)  Gulley JL, Heery CR, Madan RA, Walter BA, Merino MJ, Dahut WL, Tsang KY, Schlom J, Pinto PA.
Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.
Cancer Immunol. Immunother. 62: 1521-31, 2013.
[Journal]
12)  Schlom J, Hodge J, Palena C, Greiner J, Tsang K, Farsaci B, Madan R, Gulley J.
Prendergast G, Jaffee E, eds.
Recombinant TRICOM-based therapeutic cancer vaccines: lessons learned. In: Cancer Immunotherapy. Volume Second Edition.
Amsterdam: Elsevier; 2013. p. 309-26 [Book Chapter]
13)  Bilusic M, Madan R, Gulley J.
Curiel T, eds.
Issues in pre-clinical models, clinical trial design and analytical considerations in developing and evaluating novel cancer immunotherapies. In: Cancer Immunotherapy: Paradigms, Practice and Promise.
New York: Springer Science and Business Media; 2013. p. 455-474 [Book Chapter]
14)  Schlom J, Palena C, Gulley J, Greiner J, Tsang K, Madan R, Hodge J.
Lattime E, Gerson S, eds.
The use of T-cell costimulation to enhance the immunogenicity of tumors. In: Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation, Third Edition. Volume Third Edition.
Amsterdam: Elsevier; 2013. p. 316-32 [Book Chapter]
15)  Singh N, Hodge J, Madan R, Gulley JL.
Shurin MR, Umansky V, Malyguine A, eds.
Combining vaccines with therapies that render tumor cells more susceptible to immune mediated killing. In: The Tumor Immunoenvironment.
Netherlands: Springer; 2013. p. 621-642, Chapter 27 [Book Chapter]
16)  Madan RA, Tsang KY, Bilusic M, Vergati M, Poole DJ, Jochems C, Tucker JA, Schlom J, Giaccone G, Gulley JL.
Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer.
Oncologist. 18: 821-2, 2013.
[Journal]
17)  Jochems C, Tucker JA, Vergati M, Boyerinas B, Gulley JL, Schlom J, Tsang K.
Identification and characterization of agonist epitopes of the MUC1-C oncoprotein.
Cancer Immunol. Immunother. [Epub ahead of print], 2013.
[Journal]
18)  Singh N, Madan RA, Gulley JL.
Ipilimumab in prostate cancer.
Expert Opin Biol Ther. 13: 303-13, 2013.
[Journal]
19)  Dahut WL, Madan RA, Karakunnel JJ, Adelberg D, Gulley JL, Turkbey IB, Chau CH, Spencer SD, Mulquin M, Wright J, Parnes HL, Steinberg SM, Choyke PL, Figg WD.
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.
BJU Int. 1269-80, 2013.
[Journal]
20)  Figg WD, Chau CH, Madan RA, Gulley JL, Gao R, Sissung TM, Spencer S, Beatson M, Aragon-Ching J, Steinberg SM, Dahut WL.
Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.
Clin Genitourin Cancer. 11: 229-37, 2013.
[Journal]
21)  Campbell CT, Gulley JL, Oyelaran O, Hodge JW, Schlom J, Gildersleeve JC.
Serum Antibodies to Blood Group A Predict Survival on PROSTVAC-VF.
Clin. Cancer Res. 19: 1290-9, 2013.
[Journal]
22)  Huang J, Jochems C, Anderson AM, Talaie T, Jales A, Madan RA, Hodge JW, Tsang KY, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J.
Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity.
J. Immunol. 190: 6250-8, 2013.
[Journal]
23)  Schlom J, Jochems C, Gulley JL, Huang J.
The role of soluble CD40L in immunosuppression.
Oncoimmunology. 2: e22546, 2013.
[Journal]
24)  Gulley JL, Madan RA, Heery CR.
Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer.
Am Soc Clin Oncol Educ Book. 166-70, 2013.
[Journal]
25)  Gulley JL.
Therapeutic vaccines: The ultimate personalized therapy?.
Hum Vaccin Immunother. 9: 219-21, 2013.
[Journal]
26)  Huen N, Pang AL, Tucker JA, Lee T, Vergati M, Jochems C, Intrivici C, Cereda V, Chan W, Rennert OM, Madan RA, Gulley JL, Schlom J, Tsang KY.
Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer.
Int. J. Cancer. 373-82, 2013.
[Journal]
27)  Fallon J, Gulley JL.
World Vaccine Trials Congress 2012 Conference Summary] (World Vaccine Trials Congress 2012).
Volume 2. p. 765-7. [Meeting Proceeding]
28)  Gulley JL.
Marshall J, Weiner L, eds.
Prostate-specific antigen. In: Encyclopedia of Cancer Therapeutic Targets. Volume 1.
Springer; 2012. In Press. [Book Chapter]
29)  Remondo C, Gulley JL.
Cardino P, eds.
Immunotherapy for prostate cancer. In: Targeted Therapies for Castration-Resistant Prostate Cancer.
London: Future Science Group (FSG); 2012. In Press. [Book Chapter]
30)  Huang X, Adesunloye B, Gulley JL.
Berhardt V, eds.
Targeting testosterone pathways in prostate cancer treatment. In: Advances in Medicine and Biology. Volume 43.
New York: Nova Science Publishers; 2012. p. 61-108 [Book Chapter]
31)  Madan RA, Bilusic M, Heery C, Schlom J, Gulley JL.
Clinical evaluation of TRICOM vector therapeutic cancer vaccines.
Semin. Oncol. 39: 296-304, 2012.
[Journal]
32)  Madan RA, Heery CR, Gulley JL.
Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity.
Oncoimmunology. 1: 1167-1168, 2012.
[Journal]
33)  Heery CR, Hodge JW, Gulley JL.
Combining radiation and therapeutic cancer vaccines: a synergistic approach.
Breast Cancer Management. 1: 325-335, 2012.
[Journal]
34)  Huang J, Jochems C, Talaie T, Anderson A, Jales A, Tsang KY, Madan RA, Gulley JL, Schlom J.
Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role.
Blood. 120: 3030-8, 2012.
[Journal]
35)  Bilusic M, Gulley JL.
Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines.
Cancer Immunol. Immunother. 61: 109-17, 2012.
[Journal]
36)  Tucker JA, Jochems C, Gulley JL, Schlom J, Tsang KY.
Immunotherapy: shifting the balance of cell-mediated immunity and suppression in human prostate cancer.
Cancers (Basel). 4: 1333-48, 2012.
[Journal]
37)  Kim JW, Madan RA, Gulley JL.
Initial PSA oscillations precede prolonged stable disease in a patient treated with a therapeutic cancer vaccine.
Clin Genitourin Cancer. 10: 43-6, 2012.
[Journal]
38)  Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, Dahut WL, Schlom J, Gulley JL.
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
Lancet Oncol. 13: 501-8, 2012.
[Journal]
39)  Kamrava M, Kesarwala AH, Madan RA, Lita E, Kaushal A, Tsang K, Poole DJ, Steinberg SM, Ferrara T, Dahut W, Schlom J, Gulley JL.
Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy.
Prostate Cancer Prostatic Dis. 15: 1175-84, 2012.
[Journal]
40)  Kim JW, Gulley JL.
Poxviral vectors for cancer immunotherapy.
Expert Opin Biol Ther. 12: 463-78, 2012.
[Journal]
41)  Gulley JL, Emberton M, Kurhanewicz J, Choyke P.
Progress in prostate cancer imaging.
Urol. Oncol. 30: 938-9, 2012.
[Journal]
42)  Gulley JL, Leitman SF, Dahut W, Schlom J.
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
J. Natl. Cancer Inst. 104: 1106; author reply 1109-12, 2012.
[Journal]
43)  Tucker JA, Jochems C, Gulley JL, Schlom J, Tsang KY.
Shifting the balance of cell-mediated immunity and suppression in human prostate cancer [review].
Cancers. 4: 1333-1348, 2012.
[Journal]
44)  Madan RA, Schwaab T, Gulley JL.
Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer.
J Natl Compr Canc Netw. 10: 1505-12, 2012.
[Journal]
45)  Kurdziel KA, Shih JH, Apolo AB, Lindenberg L, Mena E, McKinney YY, Adler SS, Turkbey B, Dahut W, Gulley JL, Madan RA, Landgren O, Choyke PL.
The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology.
J. Nucl. Med. 53: 1175-84, 2012.
[Journal]
46)  Gulley JL.
Toward an off-the-shelf vaccine for B-cell malignancies.
Blood. 120: 1539-40, 2012.
[Journal]
47)  Zhu W, Chau C, Gulley J, Dahut W, Figg W.
Immunomodulating Drugs for the Treatment of Prostate Cancer. In: Immunomodulating Drugs for the Treatment of Cancer.
Baltimore: Lipincott Williams & Wilkins; 2011. p. 239-252 [Book Chapter]
48)  Gulley JL, Madan RA, Tsang KY, Arlen PM, Camphausen K, Mohebtash M, Kamrava M, Schlom J, Citrin D.
A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver.
Expert Opin Biol Ther. 11: 1409-18, 2011.
[Journal]
49)  Mohebtash M, Tsang KY, Madan RA, Huen NY, Poole DJ, Jochems C, Jones J, Ferrara T, Heery CR, Arlen PM, Steinberg SM, Pazdur M, Rauckhorst M, Jones EC, Dahut WL, Schlom J, Gulley JL.
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.
Clin. Cancer Res. 17: 7164-73, 2011.
[Journal]
50)  Vergati M, Cereda V, Madan RA, Gulley JL, Huen NY, Rogers CJ, Hance KW, Arlen PM, Schlom J, Tsang KY.
Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination.
Cancer Immunol. Immunother. 60: 197-206, 2011.
[Journal]
51)  Madan RA, Aragon-Ching JB, Gulley JL, Dahut WL.
From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer.
Expert Rev Vaccines. 10: 743-53, 2011.
[Journal]
52)  Tanno T, Rabel A, Alleyne M, Lee YT, Dahut WL, Gulley JL, Miller JL.
Hepcidin, anaemia, and prostate cancer.
BJU Int. 107: 678-9, 2011.
[Journal]
53)  Tsang KY, Gulley JL.
Highlights on FOXO3 and tumor-associated dendritic cells in prostate cancer.
Asian journal of andrology. 2011.
[Journal]
54)  Smith HA, Maricque BB, Eberhardt J, Petersen B, Gulley JL, Schlom J, McNeel DG.
IgG responses to tissue-associated antigens as biomarkers of immunological treatment efficacy.
J. Biomed. Biotechnol. 2011: 454861, 2011.
[Journal]
55)  Schlom J, Madan R, Bilusic M, Heery C, Hodge J, Gulley J.
Immune Targeting of Prostate Cancer (ASCO).
. p. 16-17. [Meeting Proceeding]
56)  Whiteside TL, Gulley JL, Clay TM, Tsang KY.
Immunologic monitoring of cellular immune responses in cancer vaccine therapy.
J. Biomed. Biotechnol. 2011: 370374, 2011.
[Journal]
57)  Gulley JL, Drake CG.
Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research.
Clin. Cancer Res. 17: 3884-91, 2011.
[Journal]
58)  Gulley JL, Madan RA, Schlom J.
Impact of tumour volume on the potential efficacy of therapeutic vaccines.
Curr Oncol. 18: e150-7, 2011.
[Journal]
59)  Cereda V, Vergati M, Huen N, di Bari MG, Jochems C, Intrivici C, Gulley JL, Apelian D, Schlom J, Tsang KY.
Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells.
Vaccine. 29: 4992-4999, 2011.
[Journal]
60)  Gulley J.
New frontiers in therapy for metastatic prostate cancer (editorial).
Drug Discov Today: Ther Strategies. 10: 743-53, 2011.
[Journal]
61)  May KF, Gulley JL, Drake CG, Dranoff G, Kantoff PW.
Prostate Cancer Immunotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research. 2011.
[Journal]
62)  Madan RA, Gulley JL.
Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer.
Expert Rev Vaccines. 10: 141-50, 2011.
[Journal]
63)  Madan RA, Gulley JL.
Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer.
Immunotherapy. 3: 27-31, 2011.
[Journal]
64)  Stein WD, Gulley JL, Schlom J, Madan RA, Dahut W, Figg WD, Ning YM, Arlen PM, Price D, Bates SE, Fojo T.
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.
Clin. Cancer Res. 17: 907-17, 2011.
[Journal]
65)  Gulley J, Arlen P, Hodge J, Schlom J.
Hong W, eds.
Vaccines and Immunostimulants. Chapter 57. In: Cancer Medicine 8.
Shelton, CT: PMPH-USA, Ltd.; 2010. p. 725-736 [Book Chapter]
66)  Madan R, Gulley J, Celestin J, Arlen P, Schlom J.
Figg W, Chau C, Small E, eds.
Cancer immunology, immunotherapeutics and vaccine approaches. In: Drug Management of Prostate Cancer.
New York: Springer; 2010. p. 305-319 [Book Chapter]
67)  Figg WD, Woo S, Zhu W, Chen X, Ajiboye AS, Steinberg SM, Price DK, Wright JJ, Parnes HL, Arlen PM, Gulley JL, Dahut WL.
A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer.
J. Urol. 183: 2219-26, 2010.
[Journal]
68)  Nesslinger NJ, Ng A, Tsang KY, Ferrara T, Schlom J, Gulley JL, Nelson BH.
A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients.
Clin. Cancer Res. 16: 4046-56, 2010.
[Journal]
69)  Sharifi N, Gulley JL, Dahut WL.
An update on androgen deprivation therapy for prostate cancer.
Endocr. Relat. Cancer. 17: R305-15, 2010.
[Journal]
70)  Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, Jones JL, Poole DJ, Higgins JP, Hodge JW, Cereda V, Vergati M, Steinberg SM, Halabi S, Jones E, Chen C, Parnes H, Wright JJ, Dahut WL, Schlom J.
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.
Cancer Immunol. Immunother. 59: 663-74, 2010.
[Journal]
71)  Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR.
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.
J. Clin. Oncol. 28: 1099-105, 2010.
[Journal]
72)  Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL, Trepel JB, Lee MJ, Kim YS, Sun H, Madan RA, Latham L, Jones E, Chen CC, Figg WD, Dahut WL.
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
J. Clin. Oncol. 28: 2070-6, 2010.
[Journal]
73)  Kantoff PW, Blumenstein BA, Gulley JL, Godfrey WR.
Reply to L. Leon et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010.
[Journal]
74)  Kelly RJ, Gulley JL, Giaccone G.
Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality.
Clin Lung Cancer. 11: 228-37, 2010.
[Journal]
75)  Madan RA, Gulley JL.
The current and emerging role of immunotherapy in prostate cancer.
Clin Genitourin Cancer. 8: 10-6, 2010.
[Journal]
76)  Madan RA, Gulley JL, Fojo T, Dahut WL.
Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.
Oncologist. 15: 969-75, 2010.
[Journal]
77)  Madan RA, Mohebtash M, Schlom J, Gulley JL.
Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design.
Expert Opin Biol Ther. 10: 19-28, 2010.
[Journal]
78)  Rotow J, Gameiro SR, Madan RA, Gulley JL, Schlom J, Hodge JW.
Vaccines as monotherapy and in combination therapy for prostate cancer.
Clin Transl Sci. 3: 116-22, 2010.
[Journal]
79)  Figg WD, Hussain MH, Gulley JL, Arlen PM, Aragon-Ching JB, Petrylak DP, Higano CS, Steinberg SM, Chatta GS, Parnes H, Wright JJ, Sartor O, Dahut WL.
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.
J. Urol. 181: 1104-13; discussion 1113, 2009.
[Journal]
80)  Mohebtash M, Gulley JL, Madan RA, Ferrara T, Arlen PM.
Cancer vaccines: current directions and perspectives in prostate cancer.
Curr. Opin. Mol. Ther. 11: 31-6, 2009.
[Journal]
81)  Ferrara TA, Hodge JW, Gulley JL.
Combining radiation and immunotherapy for synergistic antitumor therapy.
Curr. Opin. Mol. Ther. 11: 37-42, 2009.
[Journal]
82)  Arlen PM, Gulley JL.
Current perspectives in prostate cancer vaccines.
Anticancer Agents Med Chem. 9: 1052-7, 2009.
[Journal]
83)  Aragon-Ching JB, Jain L, Gulley JL, Arlen PM, Wright JJ, Steinberg SM, Draper D, Venitz J, Jones E, Chen CC, Figg WD, Dahut WL.
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
BJU Int. 103: 1636-40, 2009.
[Journal]
84)  Aragon-Ching JB, Ning YM, Chen CC, Latham L, Guadagnini JP, Gulley JL, Arlen PM, Wright JJ, Parnes H, Figg WD, Dahut WL.
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.
Cancer Invest. 27: 221-6, 2009.
[Journal]
85)  Kamrava M, Tsang KY, Madan RA, Kaushal A, Coleman CN, Gulley J.
Long-term survival and PSA control with radiation and immunotherapy for node positive prostate cancer.
Clin. Dev. Immunol. 2009: 363914, 2009.
[Journal]
86)  Cereda V, Poole DJ, Palena C, Das S, Bera TK, Remondo C, Gulley JL, Arlen PM, Yokokawa J, Pastan I, Schlom J, Tsang KY.
New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy.
Cancer Immunol. Immunother. 2009.
[Journal]
87)  Dahut WL, Aragon-Ching JB, Woo S, Tohnya TM, Gulley JL, Arlen PM, Wright JJ, Ventiz J, Figg WD.
Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
Journal of clinical pharmacology. 49: 650-60, 2009.
[Journal]
88)  Arlen PM, Mohebtash M, Madan RA, Gulley JL.
Promising novel immunotherapies and combinations for prostate cancer.
Future oncology (London, England). 5: 187-96, 2009.
[Journal]
89)  Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL.
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.
Expert opinion on investigational drugs. 18: 1001-11, 2009.
[Journal]
90)  Zhu W, Zhu DS, Madan RA, Gulley JL, Figg WD, Dahut WL.
Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway.
Am J Ther. 17: 176-81, 2009.
[Journal]
91)  Aragon-Ching J, Sharifi N, Gulley JL.
Androgens, androgen suppression, and prostate cancer: recent preclinical and clinical findings and implications. In: Testosterone Research.
Hauppauge, NY: Nova Science Publishers; 2008. p. 1-59 [Book Chapter]
92)  Dahut WL, Scripture C, Posadas E, Jain L, Gulley JL, Arlen PM, Wright JJ, Yu Y, Cao L, Steinberg SM, Aragon-Ching JB, Venitz J, Jones E, Chen CC, Figg WD.
A phase II clinical trial of sorafenib in androgen-independent prostate cancer.
Clin. Cancer Res. 14: 209-14, 2008.
[Journal]
93)  Sharifi N, Hamada A, Sissung T, Danesi R, Venzon D, Baum C, Gulley JL, Price DK, Dahut WL, Figg WD.
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer.
BJU Int. 2008.
[Journal]
94)  Madan RA, Gulley JL, Schlom J, Steinberg SM, Liewehr DJ, Dahut WL, Arlen PM.
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy.
Clin. Cancer Res. 14: 4526-31, 2008.
[Journal]
95)  Yokokawa J, Cereda V, Remondo C, Gulley JL, Arlen PM, Schlom J, Tsang KY.
Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer.
Clin. Cancer Res. 14: 1032-40, 2008.
[Journal]
96)  Gulley JL, Aragon-Ching JB, Steinberg SM, Hussain MH, Sartor O, Higano CS, Petrylak DP, Chatta GS, Arlen PM, Figg WD, Dahut WL.
Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer.
J. Urol. 180: 1432-7; discussion 1437, 2008.
[Journal]
97)  Schlom J, Gulley JL, Arlen PM.
Paradigm shifts in cancer vaccine therapy.
Exp. Biol. Med. (Maywood). 233: 522-34, 2008.
[Journal]
98)  Gulley JL, Arlen PM, Tsang KY, Yokokawa J, Palena C, Poole DJ, Remondo C, Cereda V, Jones JL, Pazdur MP, Higgins JP, Hodge JW, Steinberg SM, Kotz H, Dahut WL, Schlom J.
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.
Clin. Cancer Res. 14: 3060-9, 2008.
[Journal]
99)  Arlen PM, Bianco F, Dahut WL, D'Amico A, Figg WD, Freedland SJ, Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan MM, Sartor O.
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time.
J. Urol. 179: 2181-5; discussion 2185-6, 2008.
[Journal]
100)  Lechleider RJ, Arlen PM, Tsang KY, Steinberg SM, Yokokawa J, Cereda V, Camphausen K, Schlom J, Dahut WL, Gulley JL.
Safety and Immunologic Response of a Viral Vaccine to Prostate-Specific Antigen in Combination with Radiation Therapy when Metronomic-Dose Interleukin 2 Is Used as an Adjuvant.
Clin. Cancer Res. 14: 5284-5291, 2008.
[Journal]
101)  Hodge JW, Guha C, Neefjes J, Gulley JL.
Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges.
Oncology (Williston Park, N.Y.). 22: 1064-70; discussion 1075, 1080-1, 1084, 2008.
[Journal]
102)  Mohebtash M, Madan RA, Gulley JL, Arlen PM.
Therapeutic prostate cancer vaccines: a review of the latest developments.
Current opinion in investigational drugs (London, England : 2000). 9: 1296-301, 2008.
[Journal]
103)  O'Mahony D, Morris JC, Quinn C, Gao W, Wilson WH, Gause B, Pittaluga S, Neelapu S, Brown M, Fleisher TA, Gulley JL, Schlom J, Nussenblatt R, Albert P, Davis TA, Lowy I, Petrus M, Waldmann TA, Janik JE.
A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy.
Clin. Cancer Res. 13: 958-64, 2007.
[Journal]
104)  Schlom J, Arlen P, Gulley J.
Cancer vaccines: moving beyond current paradigms.
Clin. Cancer Res. 3776-82, 2007.
[Journal]
105)  Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, Grosenbach DW, Feldman J, Poole DJ, Litzinger M, Steinberg SM, Jones E, Chen C, Marte J, Parnes H, Wright J, Dahut W, Schlom J, Gulley JL.
Clinical safety of a viral vector based prostate cancer vaccine strategy.
J. Urol. 178: 1515-20, 2007.
[Journal]
106)  Arlen PM, Madan RA, Hodge JW, Schlom J, Gulley JL.
Combining Vaccines with Conventional Therapies for Cancer.
Update on cancer therapeutics. 2: 33-39, 2007.
[Journal]
107)  Gulley J, Madan R, Arlen P.
Enhancing efficacy of therapeutic vaccinations by combination with other modalities.
Vaccine. 25: Suppl 2:B89-96., 2007.
[Journal]
108)  Gulley JL, Dahut WL.
Future directions in tumor immunotherapy: CTLA4 blockade.
Nature clinical practice. Oncology. 4: 136-7, 2007.
[Journal]
109)  Yokokawa J, Bera TK, Palena C, Cereda V, Remondo C, Gulley JL, Arlen PM, Pastan I, Schlom J, Tsang KY.
Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4).
Int. J. Cancer. 121: 595-605, 2007.
[Journal]
110)  Aragon-Ching B, Williams K, Gulley J.
Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer.
Front Biosci. 4957-71, 2007.
[Journal]
111)  Madan RA, Arlen PM, Gulley JL.
PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma.
Expert opinion on biological therapy. 7: 543-54, 2007.
[Journal]
112)  Gulley JL, Wu S, Arlen PM, Dahut WL.
Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases.
Clinical genitourinary cancer. 5: 403-5, 2007.
[Journal]
113)  Theoret M, Arlen P, Pazdur M, Dahut W, Schlom J, Gulley J.
Phase I trial of an enhanced prostate-specific antigen-based vaccine with anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer.
Clin Genitourinary Cancer. 5: 347-50, 2007.
[Journal]
114)  Figg WD, Li H, Sissung T, Retter A, Wu S, Gulley JL, Arlen P, Wright JJ, Parnes H, Fedenko K, Latham L, Steinberg SM, Jones E, Chen C, Dahut W.
Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.
BJU Int. 99: 1047-55, 2007.
[Journal]
115)  Arlen PM, Gulley JL, Madan RA, Hodge JW, Schlom J.
Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy.
Crit. Rev. Immunol. 27: 451-62, 2007.
[Journal]
116)  Schlom J, Gulley JL, Arlen PM.
Role of vaccine therapy in cancer: biology and practice.
Current oncology (Toronto, Ont.). 14: 238-45, 2007.
[Journal]
117)  Wu SL, Jones E, Gulley JL, Arlen PM, Chen CC, Figg WD, Dahut WL.
Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone.
BJU Int. 99: 525-8, 2007.
[Journal]
118)  Madan R, Lieberman R, Gulley J, Dahut W, Arlen P.
Significant prostate-specific antigen (PSA) response to low-dose ketoconazole in a patient with non-metastatic androgen-independent prostate cancer (AIPC) and a review of the literature.
Am J Ther. 14: 310-3, 2007.
[Journal]
119)  Wu S, Dahut W, Gulley J.
The use of bisphosphonates in cancer patients.
Acta Oncologica. 581-91, 2007.
[Journal]
120)  Lattouf JB, Arlen PM, Pinto PA, Gulley JL.
A phase I feasibility study of an intraprostatic prostate-specific antigen-based vaccine in patients with prostate cancer with local failure after radiation therapy or clinical progression on androgen-deprivation therapy in the absence of local definitive therapy.
Clinical genitourinary cancer. 5: 89-92, 2006.
[Journal]
121)  Ahlers CM, Camphausen K, Citrin D, Arlen PM, Gulley JL.
A pilot trial of a carcinoembryonic antigen/ TRICOM-based vaccine and radiation to liver metastases in patients with carcinoembryonic antigen-positive solid tumors.
Clinical colorectal cancer. 6: 72-5, 2006.
[Journal]
122)  Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, Beetham P, Tsang KY, Grosenbach DW, Feldman J, Steinberg SM, Jones E, Chen C, Marte J, Schlom J, Dahut W.
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
Clin. Cancer Res. 12: 1260-9, 2006.
[Journal]
123)  Arlen PM, Pazdur M, Skarupa L, Rauckhorst M, Gulley JL.
A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229).
Clin. Breast Cancer. 7: 176-9, 2006.
[Journal]
124)  Hodge JW, Greiner JW, Tsang KY, Sabzevari H, Kudo-Saito C, Grosenbach DW, Gulley JL, Arlen PM, Marshall JL, Panicali D, Schlom J.
Costimulatory molecules as adjuvants for immunotherapy.
Front. Biosci. 11: 788-803, 2006.
[Journal]
125)  Menard C, Johann D, Lowenthal M, Muanza T, Sproull M, Ross S, Gulley J, Petricoin E, Coleman C, Whiteley G, Liotta L, Camphausen K.
Discovering clinical biomarkers of ionizing radiation exposure with serum proteomic analysis.
Cancer Res. 66: 1844-50, 2006.
[Journal]
126)  Gulley JL, Parnes HL, Wright J, Dahut WL.
Early treatment gets the benefit [letter].
J. Clin. Oncol. 24: 5172-3; author reply 5173, 2006.
[Journal]
127)  Gulley JL, Figg WD, Dahut W.
Even more cost savings?.
J Oncol Pract. 2: 202, 2006.
[Journal]
128)  Gulley J, Figg W, Dahut W.
Even more cost savings?.
J Oncol Pract. 25: 202, 2006.
[Journal]
129)  Arlen PM, Dahut WL, Gulley JL.
Immunotherapy for prostate cancer: what's the future?.
Hematol. Oncol. Clin. North Am. 20: 965-83, xi, 2006.
[Journal]
130)  Dahut WL, Lakhani NJ, Gulley JL, Arlen PM, Kohn EC, Kotz H, McNally D, Parr A, Nguyen D, Yang SX, Steinberg SM, Venitz J, Sparreboom A, Figg WD.
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors.
Cancer Biol. Ther. 5: 22-7, 2006.
[Journal]
131)  Madan RA, Gulley JL, Arlen PM.
PSA-based vaccines for the treatment of prostate cancer.
Expert review of vaccines. 5: 199-209, 2006.
[Journal]
132)  Tarassoff CP, Arlen PM, Gulley JL.
Therapeutic vaccines for prostate cancer.
Oncologist. 11: 451-62, 2006.
[Journal]
133)  Garnett CT, Greiner JW, Tsang KY, Kudo-Saito C, Grosenbach DW, Chakraborty M, Gulley JL, Arlen PM, Schlom J, Hodge JW.
TRICOM vector based cancer vaccines.
Curr. Pharm. Des. 12: 351-61, 2006.
[Journal]
134)  Abraham J, Gulley J, Allegra C, eds.
Bethesda Handbook of Clinical Oncology.
Philadelphia, PA: Lippincott Williams and Wilkins; 2005. [Book (Editor)]
135)  Arlen PM, Gulley JL.
Abraham J, Allegra CJ, Gulley J, eds.
Hematopoietic growth factors. In: Bethesda Handbook of Clinical Oncology.
Philadelphia: Lippincott Williams & Wilkins; 2005. p. 475-480 [Book Chapter]
136)  Kim GP, Gulley JL, Takimoto CH.
Abraham J, Allegra CJ, Gulley JL, eds.
Pancreatic cancer. In: Bethesda Handbook of Clinical Oncology.
Philadelphia: Lippincott Williams and Wilkins; 2005. p. 123-130 [Book Chapter]
137)  Gulley JL, Dahut W.
Abraham J, Allegra CJ, Gulley JL, eds.
Prostate cancer. In: Bethesda Handbook of Clinical Oncology.
Philadelphia: Lippincott Williams and Wilkins; 2005. p. 185-202 [Book Chapter]
138)  Gulley JL, Curt G.
Abraham J, Allegra CJ, Gulley JL, eds.
Targeted therapies. In: Bethesda Handbook of Clinical Oncology.
Philadelphia: Lippincott Williams and Wilkins; 2005. p. 555-562 [Book Chapter]
139)  Posadas EM, Gulley J, Arlen PM, Trout A, Parnes HL, Wright J, Lee M, Chung EJ, Trepel JB, Sparreboom A, Chen C, Jones E, Steinberg SM, Daniels A, Figg WD, Dahut WL.
A phase II study of perifosine in androgen independent prostate cancer.
Cancer Biol Ther. 4: 1133-7, 2005.
[Journal]
140)  Gulley JL, Figg WD, Steinberg SM, Carter J, Sartor O, Higano CS, Petrylak DP, Chatta G, Hussain MH, Dahut WL.
A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy.
J Urol. 173: 1567-71, 2005.
[Journal]
141)  Figg WD, Liu Y, Arlen P, Gulley J, Steinberg SM, Liewehr DJ, Cox MC, Zhai S, Cremers S, Parr A, Yang X, Chen CC, Jones E, Dahut WL.
A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases.
J Urol. 173: 790-6, 2005.
[Journal]
142)  Sharifi N, Dahut WL, Steinberg SM, Figg WD, Tarassoff C, Arlen P, Gulley JL.
A retrospective study of the time to clinical endpoints for advanced prostate cancer.
BJU international. 96: 985-9, 2005.
[Journal]
143)  Tsang KY, Palena C, Yokokawa J, Arlen PM, Gulley JL, Mazzara GP, Gritz L, Yafal AG, Ogueta S, Greenhalgh P, Manson K, Panicali D, Schlom J.
Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
Clin. Cancer Res. 11: 1597-607, 2005.
[Journal]
144)  Sharifi N, Gulley JL, Dahut WL.
Androgen deprivation therapy for prostate cancer.
JAMA. 294: 238-44, 2005.
[Journal]
145)  Arlen PM, Gulley JL, Todd N, Lieberman R, Steinberg SM, Morin S, Bastian A, Marte J, Tsang KY, Beetham P, Grosenbach DW, Schlom J, Dahut W.
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer.
J Urol. 174: 539-46, 2005.
[Journal]
146)  Gulley J, Dahut WL.
Clodronate in the prevention and treatment of skeletal metastasis.
Expert Rev Anticancer Ther. 5: 221-30, 2005.
[Journal]
147)  Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, Tsang KY, Yokokawa J, Hodge JW, Ménard C, Camphausen K, Coleman CN, Sullivan F, Steinberg SM, Schlom J, Dahut W.
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
Clin Cancer Res. 11: 3353-62, 2005.
[Journal]
148)  Arlen PM, Gulley JL.
Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer.
Future oncology (London, England). 1: 19-22, 2005.
[Journal]
149)  Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang KY, Slack R, Hodge JW, Doren S, Grosenbach DW, Hwang J, Fox E, Odogwu L, Park S, Panicali D, Schlom J.
Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
J Clin Oncol. 23: 720-31, 2005.
[Journal]
150)  Todd NF, Lieberman R, Gulley JL, Dahut W, Arlen PM.
Prolonged response to nilutamide in a patient with stage D0.5 prostate cancer who previously failed androgen deprivation therapy.
Am J Ther. 12: 172-4, 2005.
[Journal]
151)  Arlen PM, Gulley JL.
Therapeutic vaccines for prostate cancer: a review of clinical data.
Curr Opin Investig Drugs. 6: 592-6, 2005.
[Journal]
152)  Gulley J, Arlen P, Schlom J.
Morse M, Clay T, Lyerly H, eds.
Pox viral vaccines. In: Handbook of Cancer Vaccines.
Totowa, NJ: Humana Press; 2004. p. 175-91 [Book Chapter]
153)  Arlen P, Gulley J, Odogwu L, Marshall J.
Figg W, McLeod H, eds.
Vaccines for the treatment of cancer. In: Pharmacokinetics and Pharmacodynamics of Anti-Cancer Drugs.
Totowa, NJ: Humana Press; 2004. p. 457-73 [Book Chapter]
154)  Gulley J, Dahut W.
Devita V, Hellman S, Rosenberg S, eds.
Novel schedules of hormone therapy for prostate cancer. In: Progress in Oncology.
Sudbury, MA: Jones and Bartlett; 2004. p. 236-53 [Book Chapter]
155)  Tsang KY, Palena C, Gulley J, Arlen P, Schlom J.
A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1.
Clin. Cancer Res. 10: 2139-49, 2004.
[Journal]
156)  Tohnya TM, Ng SS, Dahut WL, Wright JJ, Arlen PM, Gulley JL, Parker C, Zeldis J, Figg WD.
A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer.
Clin Prostate Cancer. 2: 241-3, 2004.
[Journal]
157)  Gulley J, Dahut WL.
Chemotherapy for prostate cancer: finally an advance!.
Am J Ther. 11: 288-94, 2004.
[Journal]
158)  Schlom J, Palena C, Greiner JW, Tsang KY, Grosenbach DW, Sabzevari H, Gulley JL, Arlen PM, Kass E, Hodge JW.
Combinatorial vaccine strategies and the use of molecular arrays to characterize T-cell activation.
Developments in biologicals. 116: 27-47, 2004.
[Journal]
159)  Retter AS, Gulley JL, Dahut WL.
Novel therapeutic strategies in prostate cancer.
Cancer Biol Ther. 3: 371-6, 2004.
[Journal]
160)  Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, Wright JJ, Parnes H, Chen CC, Jones E, Parker CE, Linehan WM, Figg WD.
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer.
J Clin Oncol. 22: 2532-9, 2004.
[Journal]
161)  Posadas EM, Dahut WL, Gulley J.
The emerging role of bisphosphonates in prostate cancer.
Am J Ther. 11: 60-73, 2004.
[Journal]
162)  Arlen PM, Gulley JL.
Therapeutic vaccines for colorectal cancer: a review of clinical data.
Am J Cancer. 3: 299-316, 2004.
[Journal]
163)  Arlen PM, Gulley JL, Dahut W.
Vaccine therapy for a patient with androgen-insensitive prostate cancer without evidence of measurable disease on scans.
Am J Ther. 11: 238-41, 2004.
[Journal]
164)  Arlen PM, Gulley JL, Palena C, Marshall J, Schlom J, Tsang KY.
A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1.
J. Immunol. Methods. 279: 183-92, 2003.
[Journal]
165)  Leonard GD, Dahut WL, Gulley JL, Arlen PM, Figg WD.
Docetaxel and thalidomide as a treatment option for androgen- independent, nonmetastatic prostate cancer.
Reviews in urology. 5 Suppl 3: S65-70, 2003.
[Journal]
166)  Horne MK, Figg WD, Arlen P, Gulley J, Parker C, Lakhani N, Parnes H, Dahut WL.
Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.
Pharmacotherapy. 23: 315-8, 2003.
[Journal]
167)  Gulley J, Dahut WL.
Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient.
Urology. 62 Suppl 1: 147-54, 2003.
[Journal]
168)  Behrens RJ, Gulley JL, Dahut WL.
Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide.
Am J Ther. 10: 228-32, 2003.
[Journal]
169)  Arlen PM, Gulley JL, Tsang KY, Schlom J.
Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.
Expert Rev Vaccines. 2: 483-93, 2003.
[Journal]
170)  Gulley J, Figg WD, Dahut WL.
Treatment options for androgen-independent prostate cancer.
Clin Adv Hematol Oncol. 1: 49-57, 2003.
[Journal]
171)  Terasawa H, Tsang KY, Gulley J, Arlen P, Schlom J.
Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.
Clin. Cancer Res. 8: 41-53, 2002.
[Journal]
172)  Arlen PM, Figg WD, Gulley J, Cox MC, Linehan WM, Dahut W.
National Cancer Institute intramural approach to advanced prostate cancer.
Clin Prostate Cancer. 1: 153-62, 2002.
[Journal]
173)  Gulley J, Dahut W.
Novel clinical trials in androgen-independent prostate cancer.
Clin Prostate Cancer. 1: 51-7, 2002.
[Journal]
174)  Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, Tsang K, Panicali D, Poole D, Schlom J, Michael Hamilton J.
Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.
Prostate. 53: 109-17, 2002.
[Journal]
175)  Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, Hamilton M, Parker C, Kruger EA, Pluda J, Dahut WL.
A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.
Semin. Oncol. 28: 62-6, 2001.
[Journal]
176)  Tsang KY, Zhu M, Even J, Gulley J, Arlen P, Schlom J.
The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.
Cancer Res. 61: 7568-76, 2001.
[Journal]
177)  von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, Alpaugh RK, Davey M, McLaughlin S, Beard MT, Tsang KY, Schlom J, Weiner LM.
The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
Clin. Cancer Res. 7: 1181-91, 2001.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 4/2/2014.